Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 2, 2018. The Company is an emerging growth company incorporated in Delaware. The report details a strategic operational event involving Napo Pharmaceuticals, Inc., the Company's wholly-owned human health subsidiary.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate event rather than financial performance results.
Material Changes
On March 2, 2018, Napo Pharmaceuticals, Inc. entered into an agreement with specialty pharmaceutical supplier Transition Patient Services. This partnership is designed to streamline and expand nationwide patient access to Mytesi (crofelemer), Napo's FDA-approved, first-in-class anti-secretory human prescription drug.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational context of the new agreement. The primary purpose of the filing is to disclose the execution of the patient access agreement.
Key Facts for Investor Verification
- Confirmation of the agreement terms between Napo Pharmaceuticals and Transition Patient Services.
- Impact of the new partnership on the distribution and market reach of Mytesi.
- Any associated costs or revenue implications of the agreement not detailed in this 8-K.